FDA has completed an inspection of Cambrex's active pharmaceutical ingredient (API) manufacturing facility in Charles City, Iowa.
Subscribe to our email newsletter
The inspectors, who visited the facility in February 2012, found that the site is compliant with the principles and guidelines of GMP.
Cambrex operations vice president and Charles City site director Joe Nettleton said, "We work diligently to maintain high quality standards and we have once again demonstrated the results of our efforts to sustain and continuously improve quality platforms within Cambrex."
The complete facility and the quality systems used for the manufacture and release of APIs and food grade products were subject to a detailed compliance inspection.